VACCINEX, INC. (VCNX)
2024-09-30 | ||||
---|---|---|---|---|
Revenue from contract with customer, excluding assessed tax | 52 | |||
Research and development expense | 3,165 | |||
General and administrative expense | 1,439 | |||
Costs and expenses | 4,604 | |||
Operating income (loss) | -4,552 | |||
Change in fair value of warrant liabilities | 71 | |||
Other nonoperating income (expense) | -3 | |||
Loss on settlement of warrants | -1,106 | |||
Income (loss) from continuing operations before income taxes, noncontrolling interest | -5,732 | |||
Net loss attributable to vaccinex, inc. common stockholders | -5,732 | |||
Basic eps | -2.83 | |||
Diluted eps | -2.83 | |||
Basic average shares | 2,026,920 | |||
Diluted average shares | 2,026,920 |